<h4>Background</h4>Identifying biomarkers that predict adverse outcomes after percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) could improve risk stratification and guide clinical management.<h4>Objectives</h4>To evaluate the prognostic value of pre-procedural IL-18, hs-CRP, and VEGF levels in predicting major adverse cardiovascular events (MACEs) in AMI patients undergoing PCI. This evidence concerns the gene IL18 and myocardial infarction.